- Disease: Acute COVID-19
- Study type: Observational Cohort Study, Treatment
- Study type descriptors: Prospective, Single centre
- Objective: To evaluate the effectiveness and safety of remdesivir and SARS-CoV-2 monoclonal antibodies in preventing COVID-19 progression in patients with hematological malignancies and mild-to-moderate disease in real clinical practice
- Number of participants enrolled: 55
- Study enrolling from to
- Study includes follow-up for 5.5 months
Study Data
- Adults (18-64 years)
- Elderly (≥65 years)
- Fragile population
- Immunocompromised host
- Hospital
- SARS-CoV-2
- Acute COVID-19
- Pharmacological intervention
- Antivirals
- Remdesivir
External Links
Other information
The information was provided with the aid of the study investigators
If you would like to contact the Principal Investigator of the study please email: ccb@ateneo.univr.it
The data is updated up to